These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 19616743)

  • 1. Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials.
    Viani GA; Stefano EJ; Afonso SL
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1405-18. PubMed ID: 19616743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose conformal radiotherapy reduces prostate cancer-specific mortality: results of a meta-analysis.
    Viani GA; da Silva LG; Stefano EJ
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e619-25. PubMed ID: 22768991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High dose versus conventional dose in external beam radiotherapy of prostate cancer: a meta-analysis of long-term follow-up.
    Hou Z; Li G; Bai S
    J Cancer Res Clin Oncol; 2015 Jun; 141(6):1063-71. PubMed ID: 25173623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose radiotherapy with or without androgen deprivation therapy for intermediate-risk prostate cancer: cancer control and toxicity outcomes.
    Edelman S; Liauw SL; Rossi PJ; Cooper S; Jani AB
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1473-9. PubMed ID: 22245201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy.
    Cheung R; Tucker SL; Lee AK; de Crevoisier R; Dong L; Kamat A; Pisters L; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):993-1002. PubMed ID: 15752878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and toxicity of external-beam radiation therapy for localised prostate cancer: a network meta-analysis.
    Zhu Z; Zhang J; Liu Y; Chen M; Guo P; Li K
    Br J Cancer; 2014 May; 110(10):2396-404. PubMed ID: 24736585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial.
    Zietman AL; DeSilvio ML; Slater JD; Rossi CJ; Miller DW; Adams JA; Shipley WU
    JAMA; 2005 Sep; 294(10):1233-9. PubMed ID: 16160131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved biochemical disease-free survival of men younger than 60 years with prostate cancer treated with high dose conformal external beam radiotherapy.
    Zelefsky MJ; Marion C; Fuks Z; Leibel SA
    J Urol; 2003 Nov; 170(5):1828-32. PubMed ID: 14532785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
    Zelefsky MJ; Fuks Z; Hunt M; Lee HJ; Lombardi D; Ling CC; Reuter VE; Venkatraman ES; Leibel SA
    J Urol; 2001 Sep; 166(3):876-81. PubMed ID: 11490237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
    Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of gynecomastia and breast pain caused by androgen deprivation therapy in prostate cancer: tamoxifen or radiotherapy?
    Viani GA; Bernardes da Silva LG; Stefano EJ
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e519-24. PubMed ID: 22704706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose escalated external beam radiotherapy versus neoadjuvant androgen deprivation therapy and conventional dose external beam radiotherapy for clinically localized prostate cancer: do we need both?
    Roach M
    Strahlenther Onkol; 2007 Dec; 183 Spec No 2():26-8. PubMed ID: 18167004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.
    Lettmaier S; Lotter M; Kreppner S; Strnad A; Fietkau R; Strnad V
    Radiother Oncol; 2012 Aug; 104(2):181-6. PubMed ID: 22853851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
    Wong WW; Schild SE; Vora SA; Halyard MY
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):24-9. PubMed ID: 15337536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in toxicity and outcome associated with circadian variations between patients undergoing daytime and evening radiotherapy for prostate adenocarcinoma.
    Hsu FM; Hou WH; Huang CY; Wang CC; Tsai CL; Tsai YC; Yu HJ; Pu YS; Cheng JC
    Chronobiol Int; 2016; 33(2):210-9. PubMed ID: 26818960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypofractionated radiation therapy (66 Gy in 22 fractions at 3 Gy per fraction) for favorable-risk prostate cancer: long-term outcomes.
    Patel N; Faria S; Cury F; David M; Duclos M; Shenouda G; Ruo R; Souhami L
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):534-9. PubMed ID: 23597418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.
    Fitch DL; McGrath S; Martinez AA; Vicini FA; Kestin LL
    Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1430-9. PubMed ID: 16765527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inverse relationship between biochemical outcome and acute toxicity after image-guided radiotherapy for prostate cancer.
    Vesprini D; Catton C; Jacks L; Lockwood G; Rosewall T; Bayley A; Chung P; Gospodarowicz M; Ménard C; Milosevic M; Nichol A; Skala M; Warde P; Bristow RG
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):608-16. PubMed ID: 22099034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer.
    Zelefsky MJ; Kollmeier M; Cox B; Fidaleo A; Sperling D; Pei X; Carver B; Coleman J; Lovelock M; Hunt M
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):125-9. PubMed ID: 22330997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.